A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

NCT05729074 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate Atopic Dermatitis

Interventions

DRUG: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment
DRUG: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment
DRUG: IN-A002 Ointment 1% or IN-A002 Placebo Ointment
DRUG: IN-A002 Ointment 3% or IN-A002 Placebo Ointment
DRUG: IN-A002 Ointment 5% or IN-A002 Placebo Ointment
DRUG: IN-A002 Ointment 1%
DRUG: IN-A002 Ointment 3%
DRUG: Elidel Cream 1% (pimecrolimus)

Sponsor

HK inno.N Corporation